Adverse effects may include irritability, drowsiness, nightmares, vertigo, nausea or vomiting, visual disturbances or hallucinations, and urticaria. There are potential interactions with other anticholinergics, CNS depressants, and alcohol.[3]
Chlophedianol was approved for OTC status in 1987 by the FDA OTC monograph process[5] and its safety and efficacy data are limited. It was formerly sold over-the-counter in the United States under the trade name Ulo, as a syrup with a dosage of 25 mg/5 mL.[6] It is now marketed under the brand name of Ninjacof in the U.S.
It is marketed in Canada under the trade name Ulone. GM Pharmaceuticals owns the patents to 113 combinations with Chlophedianol and was the first company to launch the cough suppressant in the United States.[7]
It is sold in Japan as an over-the-counter drug under the name Coldrin.[8] It has been marketed in Germany as Pectolitan and in Spain as Gentos.[9]
^Martín AV (2004). "Tratamiento sintomático de la tos y del resfriado común". Farmacología clínica y terapéutica médica. McGraw-Hill/Interamericana. p. 260. ISBN9788448604271.
^"Clofedanol" (in French). BIAM. 1998-07-24. Retrieved 2007-04-15.
^Schlesser JL (1991). Drugs Available Abroad, 1st Edition. Derwent Publications Ltd. p. 29. ISBN0-8103-7177-4.
^Klein M, Musacchio JM (October 10, 1988). "Dextromethorphan binding sites in the guinea pig brain". Cellular and Molecular Neurobiology. 8 (2): 149–156. doi:10.1007/BF00711241. PMID3044591. S2CID33844132.